Vericel Corp. (VCEL)
41.11
+0.96
(+2.39%)
USD |
NASDAQ |
Oct 05, 16:00
41.11
0.00 (0.00%)
After-Hours: 16:03
Vericel Enterprise Value : 1.987B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.987B |
| October 01, 2026 | 1.950B |
| September 30, 2026 | 1.986B |
| September 29, 2026 | 2.010B |
| September 28, 2026 | 1.991B |
| September 25, 2026 | 1.964B |
| September 24, 2026 | 1.943B |
| September 23, 2026 | 1.917B |
| September 22, 2026 | 1.990B |
| September 21, 2026 | 1.956B |
| September 18, 2026 | 1.980B |
| September 17, 2026 | 1.980B |
| September 16, 2026 | 1.990B |
| September 15, 2026 | 1.965B |
| September 14, 2026 | 1.958B |
| September 11, 2026 | 1.894B |
| September 10, 2026 | 1.870B |
| September 09, 2026 | 1.927B |
| September 08, 2026 | 1.932B |
| September 04, 2026 | 1.989B |
| September 03, 2026 | 2.003B |
| September 02, 2026 | 2.024B |
| September 01, 2026 | 2.005B |
| August 31, 2026 | 1.974B |
| August 28, 2026 | 2.028B |
| Date | Value |
|---|---|
| August 27, 2026 | 2.039B |
| August 26, 2026 | 2.104B |
| August 25, 2026 | 2.144B |
| August 24, 2026 | 2.097B |
| August 21, 2026 | 2.116B |
| August 20, 2026 | 2.087B |
| August 19, 2026 | 2.162B |
| August 18, 2026 | 2.197B |
| August 17, 2026 | 2.163B |
| August 14, 2026 | 2.194B |
| August 13, 2026 | 2.211B |
| August 12, 2026 | 2.221B |
| August 11, 2026 | 2.202B |
| August 10, 2026 | 2.181B |
| August 07, 2026 | 2.239B |
| August 06, 2026 | 2.222B |
| August 05, 2026 | 2.253B |
| August 04, 2026 | 2.303B |
| August 03, 2026 | 2.289B |
| July 31, 2026 | 2.284B |
| July 30, 2026 | 2.368B |
| July 29, 2026 | 2.318B |
| July 28, 2026 | 2.322B |
| July 27, 2026 | 2.251B |
| July 24, 2026 | 2.237B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 528.72B |
| ADMA Biologics, Inc. | 2.258B |
| Kyntra Bio, Inc. | -43.77M |
| Conexeu Sciences, Inc. | 82.79M |
| ACADIA Pharmaceuticals, Inc. | 2.551B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.206M |
| Revenue (Quarterly) | 77.46M |
| Total Expenses (Quarterly) | 75.25M |
| EPS Diluted (Quarterly) | 0.0422 |
| Gross Profit Margin (Quarterly) | 72.82% |
| Profit Margin (Quarterly) | 2.85% |
| Earnings Yield | 1.12% |
| Operating Earnings Yield | 0.86% |
| Normalized Earnings Yield | 1.124 |